Olaparib in Patients With HRD Malignant Mesothelioma

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Chicago
Study ID
NCT04515836
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Homologous Recombination Deficiency
  • Mesothelioma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Olaparib — DRUG
    Olaparib is a chemotherapy drug (packaged as a pill) that can be taken by mouth, twice daily.

Study Details

In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient's tumor shrink or stop growing.

Key Dates

Start date
Feb 19, 2021
Status verified
May 2025
Primary completion
Apr 15, 2028
Completion
Apr 15, 2028

Study Design

Enrollment
56 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Arm
    Olaparib will be given orally to patients in 28-day cycles. Patients will attend the clinic on days 1 (first day of treatment) and 15 of the first cycle following the beginning of study treatment and then every 4 weeks (day 1 of every cycle) until discontinuation of treatment.

Primary Outcome Measure

Objective Response Rate of Patients to Olaparib [ Time Frame: Two years. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Chicago Medical CenterChicagoIllinois60615-

Find similar trials in Chicago, IL

By research site
University of Chicago Medical Center· Chicago, IL

Related Studies